Prognostic relevance of Bmi-1 expression and autoantibodies in esophageal squamous cell carcinoma

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Liu, Wan Li ^a   Guo, Xian Zhi ^b   Zhang, Lan Jun ^a   Wang, Jun Ye ^a   Zhang, Ge ^c   Guan, Su ^a   Chen, Yu Min ^c   Kong, Qing Li ^a   Xu, Li Hua ^a   Li, Man Zhi ^a   Song, Li Bing ^a   Zeng, Mu Sheng ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b The Central Hospital of Xuhui District   (China)

^c SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; BMI1 PROTEIN; MESSENGER RNA; PROTEIN ANTIBODY; BMI1 PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN; REPRESSOR PROTEIN;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER CLASSIFICATION; CANCER STAGING; CANCER SURVIVAL; CANCER TISSUE; CELL IMMORTALIZATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS CANCER; ESOPHAGUS TUMOR; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL; WESTERN BLOTTING; BLOOD; CASE CONTROL STUDY; COMPARATIVE STUDY; ENZYME IMMUNOASSAY; GENETICS; IMMUNOLOGY; METABOLISM; METASTASIS; MIDDLE AGED; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; TUMOR CELL CULTURE;

ADULT; AGED; AGED, 80 AND OVER; AUTOANTIBODIES; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; NEOPLASM STAGING; NUCLEAR PROTEINS; PROGNOSIS; PROTO-ONCOGENE PROTEINS; REPRESSOR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TUMOR CELLS, CULTURED;

EID: 77956478255     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-467     Document Type: Article

References (38)

1. Enzinger PC, Mayer RJ. Esophageal cancer. The New England journal of medicine 2003, 349(23):2241-2252. 10.1056/NEJMra035010, 14657432.
2. Lam KY, Ma L. Pathology of esophageal cancers: local experience and current insights. Chinese medical journal 1997, 110(6):459-464.
3. Zhang H, Jin Y, Chen X, Jin C, Law S, Tsao SW, Kwong YL. Cytogenetic aberrations in immortalization of esophageal epithelial cells. Cancer genetics and cytogenetics 2006, 165(1):25-35. 10.1016/j.cancergencyto.2005.07.016, 16490594.
4. Cervantes J. Update on the pathogenesis and immunotherapy of esophageal squamous cell carcinoma. Rev Gastroenterol Peru 2004, 24(2):165-170.
5. Naitoh H, Shibata J, Kawaguchi A, Kodama M, Hattori T. Overexpression and localization of cyclin D1 mRNA and antigen in esophageal cancer. The American journal of pathology 1995, 146(5):1161-1169. 1869295, 7747810.
6. Kakegawa T, Yamana H. Postoperative prognostic factors for carcinoma of the thoracic esophagus. Gan to kagaku ryoho 1995, 22(4):573-579.
7. Iizuka N, Tangoku A, Hayashi H, Yosino S, Abe T, Morioka T, Oka M. The association between nm23-H1 expression and survival in patients with esophageal squamous cell carcinoma. Cancer letters 1999, 138(1-2):139-144. 10.1016/S0304-3835(98)00387-5, 10378785.
8. Chan KW, Lee PY, Lam AK, Law S, Wong J, Srivastava G. Clinical relevance of Fas expression in oesophageal squamous cell carcinoma. Journal of clinical pathology 2006, 59(1):101-104. 10.1136/jcp.2005.027508, 1860271, 16394289.
9. Guo XZ, Zhang G, Wang JY, Liu WL, Wang F, Dong JQ, Xu LH, Cao JY, Song LB, Zeng MS. Prognostic relevance of Centromere protein H expression in esophageal carcinoma. BMC cancer 2008, 8:233. 10.1186/1471-2407-8-233, 2535782, 18700042.
10. Haupt Y, Alexander WS, Barri G, Klinken SP, Adams JM. Novel zinc finger gene implicated as myc collaborator by retrovirally accelerated lymphomagenesis in E mu-myc transgenic mice. Cell 1991, 65(5):753-763. 10.1016/0092-8674(91)90383-A, 1904009.
11. van Lohuizen M, Verbeek S, Scheijen B, Wientjens E, van der Gulden H, Berns A. Identification of cooperating oncogenes in E mu-myc transgenic mice by provirus tagging. Cell 1991, 65(5):737-752. 10.1016/0092-8674(91)90382-9, 1904008.
12. van der Lugt NM, Domen J, Linders K, van Roon M, Robanus-Maandag E, te Riele H, van der Valk M, Deschamps J, Sofroniew M, van Lohuizen M, et al. Posterior transformation, neurological abnormalities, and severe hematopoietic defects in mice with a targeted deletion of the bmi-1 proto-oncogene. Genes & development 1994, 8(7):757-769.
13. Pirrotta V. Polycombing the genome: PcG, trxG, and chromatin silencing. Cell 1998, 93(3):333-336. 10.1016/S0092-8674(00)81162-9, 9590168.
14. Jacobs JJ, Kieboom K, Marino S, DePinho RA, van Lohuizen M. The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature 1999, 397(6715):164-168. 10.1038/16476, 9923679.
15. Dimri GP, Martinez JL, Jacobs JJ, Keblusek P, Itahana K, Van Lohuizen M, Campisi J, Wazer DE, Band V. The Bmi-1 oncogene induces telomerase activity and immortalizes human mammary epithelial cells. Cancer research 2002, 62(16):4736-4745.
16. Song LB, Zeng MS, Liao WT, Zhang L, Mo HY, Liu WL, Shao JY, Wu QL, Li MZ, Xia YF, et al. Bmi-1 is a novel molecular marker of nasopharyngeal carcinoma progression and immortalizes primary human nasopharyngeal epithelial cells. Cancer Res 2006, 66(12):6225-6232. 10.1158/0008-5472.CAN-06-0094, 16778197.
17. Tong YQ, Liu B, Huang J, Liu Y, Guo FJ, Zhou GH, Xie PL, Li YH, Hu JY, Li GC. BMI-1 autoantibody in serum as a new potential biomarker of nasopharyngeal carcinoma. Cancer biology & therapy 2008, 7(3):340-344.
18. Bea S, Tort F, Pinyol M, Puig X, Hernandez L, Hernandez S, Fernandez PL, van Lohuizen M, Colomer D, Campo E. BMI-1 gene amplification and overexpression in hematological malignancies occur mainly in mantle cell lymphomas. Cancer research 2001, 61(6):2409-2412.
19. Vonlanthen S, Heighway J, Altermatt HJ, Gugger M, Kappeler A, Borner MM, van Lohuizen M, Betticher DC. The bmi-1 oncoprotein is differentially expressed in non-small cell lung cancer and correlates with INK4A-ARF locus expression. British journal of cancer 2001, 84(10):1372-1376. 10.1054/bjoc.2001.1791, 2363629, 11355949.
20. van Kemenade FJ, Raaphorst FM, Blokzijl T, Fieret E, Hamer KM, Satijn DP, Otte AP, Meijer CJ. Coexpression of BMI-1 and EZH2 polycomb-group proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma. Blood 2001, 97(12):3896-3901. 10.1182/blood.V97.12.3896, 11389032.
21. Kim JH, Yoon SY, Jeong SH, Kim SY, Moon SK, Joo JH, Lee Y, Choe IS, Kim JW. Overexpression of Bmi-1 oncoprotein correlates with axillary lymph node metastases in invasive ductal breast cancer. Breast (Edinburgh, Scotland) 2004, 13(5):383-388.
22. Kim JH, Yoon SY, Kim CN, Joo JH, Moon SK, Choe IS, Choe YK, Kim JW. The Bmi-1 oncoprotein is overexpressed in human colorectal cancer and correlates with the reduced p16INK4a/p14ARF proteins. Cancer letters 2004, 203(2):217-224. 10.1016/j.canlet.2003.07.009, 14732230.
23. Glinsky GV, Berezovska O, Glinskii AB. Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. The Journal of clinical investigation 2005, 115(6):1503-1521. 10.1172/JCI23412, 1136989, 15931389.
24. Liu JH, Song LB, Zhang X, Guo BH, Feng Y, Li XX, Liao WT, Zeng MS, Huang KH. Bmi-1 expression predicts prognosis for patients with gastric carcinoma. Journal of surgical oncology 2008, 97(3):267-272. 10.1002/jso.20934, 18041745.
25. He XT, Cao XF, Ji L, Zhu B, Lv J, Wang DD, Lu PH, Cui HG. Association between Bmi1 and clinicopathological status of esophageal squamous cell carcinoma. World J Gastroenterol 2009, 15(19):2389-2394. 10.3748/wjg.15.2389, 2684608, 19452584.
26. Sobin LH, Fleming ID. TNM Classification of Malignant Tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer 1997, 80(9):1803-1804. 10.1002/(SICI)1097-0142(19971101)80:9<1803::AID-CNCR16>3.0.CO;2-9, 9351551.
27. Ciocca DR, Clark GM, Tandon AK, Fuqua SA, Welch WJ, McGuire WL. Heat shock protein hsp70 in patients with axillary lymph node-negative breast cancer: prognostic implications. Journal of the National Cancer Institute 1993, 85(7):570-574. 10.1093/jnci/85.7.570, 8455204.
28. Mandard AM, Hainaut P, Hollstein M. Genetic steps in the development of squamous cell carcinoma of the esophagus. Mutation research 2000, 462(2-3):335-342. 10.1016/S1383-5742(00)00019-3, 10767643.
29. Shay JW, Wright WE. Senescence and immortalization: role of telomeres and telomerase. Carcinogenesis 2005, 26(5):867-874. 10.1093/carcin/bgh296, 15471900.
30. Dawsey SM, Wang GQ, Weinstein WM, Lewin KJ, Liu FS, Wiggett S, Nieberg RK, Li JY, Taylor PR. Squamous dysplasia and early esophageal cancer in the Linxian region of China: distinctive endoscopic lesions. Gastroenterology 1993, 105(5):1333-1340.
31. Shiozaki H, Doki Y, Kawanishi K, Shamma A, Yano M, Inoue M, Monden M. Clinical application of malignancy potential grading as a prognostic factor of human esophageal cancers. Surgery 2000, 127(5):552-561. 10.1067/msy.2000.105028, 10819064.
32. Eloubeidi MA, Desmond R, Arguedas MR, Reed CE, Wilcox CM. Prognostic factors for the survival of patients with esophageal carcinoma in the U.S.: the importance of tumor length and lymph node status. Cancer 2002, 95(7):1434-1443. 10.1002/cncr.10868, 12237911.
33. Veale RB, Thornley AL, Scott E, Antoni A, Segal I. Quantitation of autoantibodies to cytokeratins in sera from patients with squamous cell carcinoma of the oesophagus. Br J Cancer 1988, 58(6):767-772. 2246860, 2465018.
34. Bergqvist AS, Bergqvist M, Brattstrom D, Hesselius P, Larsson A, Brodin O, Wagenius G. Serum p53 autoantibodies as prognostic marker in patients with oesophageal carcinoma. Anticancer Res 2001, 21(6A):4141-4145.
35. Kuboshima M, Shimada H, Liu TL, Nomura F, Takiguchi M, Hiwasa T, Ochiai T. Presence of serum tripartite motif-containing 21 antibodies in patients with esophageal squamous cell carcinoma. Cancer Sci 2006, 97(5):380-386. 10.1111/j.1349-7006.2006.00192.x, 16630135.
36. Shimada H, Kuboshima M, Shiratori T, Nabeya Y, Takeuchi A, Takagi H, Nomura F, Takiguchi M, Ochiai T, Hiwasa T. Serum anti-myomegalin antibodies in patients with esophageal squamous cell carcinoma. Int J Oncol 2007, 30(1):97-103.
37. Fujita Y, Nakanishi T, Hiramatsu M, Mabuchi H, Miyamoto Y, Miyamoto A, Shimizu A, Tanigawa N. Proteomics-based approach identifying autoantibody against peroxiredoxin VI as a novel serum marker in esophageal squamous cell carcinoma. Clin Cancer Res 2006, 12(21):6415-6420. 10.1158/1078-0432.CCR-06-1315, 17085654.
38. Liu WL, Zhang G, Wang JY, Cao JY, Guo XZ, Xu LH, Li MZ, Song LB, Huang WL, Zeng MS. Proteomics-based identification of autoantibody against CDC25B as a novel serum marker in esophageal squamous cell carcinoma. Biochem Biophys Res Commun 2008, 375(3):440-445. 10.1016/j.bbrc.2008.08.039, 18722351.